Schizophrenia

2 trends tracked about this subject — the full history, oldest to newest below.

▲ Peaking Business 🔮 holds

MapLight Therapeutics shares declined following the release of mixed Phase 2 trial results for its schizophrenia drug candidate.

7 sources 7 articles v 5 just now

◼ Archived Health 🔮 holds ✗

6 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.

6 sources 6 articles v 4 11d ago